DOI QR코드

DOI QR Code

Clinical Value of Eukaryotic Elongation Factor 2 (eEF2) in Non-small Cell Lung Cancer Patients

  • Sun, Hong-Gang (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
  • Dong, Xue-Jun (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
  • Lu, Tao (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
  • Yang, Ming-Feng (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
  • Wang, Xing-Mu (Clinical Laboratory Center of Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)
  • Published : 2013.11.30

Abstract

Background: The purpose of this study was to evaluate a new type of tumor biomarker, eukaryotic elongation factor 2 (eEF2), in serum for the early diagnosis, confirmative diagnosis as well as assessment of treatment of non-small cell lung cancer (NSCLC). Methods: 130 patients with NSCLC and 50 healthy individuals undergoing physical examination in our hospital provided the observation and healthy control groups. An enzyme linked immune sorbent assay (ELISA) method was applied to determine serum eEF2 levels. Serum neuron specific enolase (NSE) and squamous cell carcinoma antigen (SCC) levels in the observation group were assessed with an automatic biochemical analyzer. Results: The median levels of eEF2 in the serum of NSCLC patients was found to be significantly higher than the healthy control group (p < 0.01) and it was markedly higher in stages III, IV than stages I, II (p < 0.05). eEF2 was higher with tumor size ${\geq}2$ cm than <2 cm (P< 0.01). Furthermore, two weeks after surgery patients showed a significant trend for eEF2 decrease (p < 0.05). Conclusions: The eukaryotic elongation factor 2 (eEF2) has certain clinical values for early diagnosis, verification, and prognosis as well as classification of lung cancer patients.

Keywords

Non-small cell lung cancer;eukaryotic elongation factor 2;clinical value

References

  1. Adcock IM, Caramori G, Barnes PJ (2011)..Chronic obstructive pulmonary disease and lung cancer: new molecular insights..Respiration, 81, 265-84. https://doi.org/10.1159/000324601
  2. Chen CY, Fang HY, Chiou SH, et al (2011). Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer Sci, 102, 1582-9. https://doi.org/10.1111/j.1349-7006.2011.01975.x
  3. Hensing TA, Salgia R (2013). Molecular biomarkers for future screening of lung cancer. J Surg Oncol, 108, 327-33. https://doi.org/10.1002/jso.23382
  4. Karp DD, Lee SJ, Keller SM, et al (2013). Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer: ECOG 5597. J Clin Oncol, 9, 1-12
  5. Leprivier G, Remke M, Rotblat B, et al (2013). The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell, 153, 1064-79. https://doi.org/10.1016/j.cell.2013.04.055
  6. Liang J, Qian Y, Xu D, et al (2013). Serum tumor markers, hypoxia-inducible factor-1$\alpha$ HIF-1$\alpha$ and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention. Asian Pac J Cancer Prev, 14, 3851-4. https://doi.org/10.7314/APJCP.2013.14.6.3851
  7. Massion PP, Carbone DP (2003).The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respir Res, 4, 1-15. https://doi.org/10.1186/rr196
  8. Nakamura J, Aoyagi S, Nanchi I, et al (2009). Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int J Oncol, 34, 1181-9.
  9. Siegel R, Naishadham D, Jemal A (2012). Cancer Journal for Clinicians. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138

Cited by

  1. Shared signatures between rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome uncovered through gene expression meta-analysis vol.16, pp.6, 2014, https://doi.org/10.1186/s13075-014-0489-x
  2. Bouvardin is a Radiation Modulator with a Novel Mechanism of Action vol.184, pp.4, 2015, https://doi.org/10.1667/RR14068.1
  3. Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells vol.20, pp.2, 2015, https://doi.org/10.1007/s12192-014-0545-0
  4. Eukaryotic Elongation Factor 2 (eEF2) is a Potential Biomarker of Prostate Cancer pp.1532-2807, 2017, https://doi.org/10.1007/s12253-017-0302-7
  5. The expression profile and prognostic significance of eukaryotic translation elongation factors in different cancers vol.13, pp.1, 2018, https://doi.org/10.1371/journal.pone.0191377